Stock Ratings / Health Care / MYGN / financials

ACHV (44) NNNN (45) TKNO (44) QDEL (30) ⌘ Pro Terminal →

Myriad Genetics Inc. (MYGN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.67 +0.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Myriad Genetics Inc. (MYGN) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $638.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MYGN)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How MYGN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$1.8M (0.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $753.2M

FY24

Rev $837.6M

FY25

Rev $824.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$824.5M	69.9%	-47%	-$366.0M	$1.8M	-45%
FY 2024	$837.6M	69.9%	-14.7%	-$127.0M	-$8.7M	-15.3%
FY 2023	$753.2M	69.9%	-34.2%	-$263.0M	-$110.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MYGN)

✓Walkthrough of MYGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MYGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +40.42%▲ RESISTANCE BREAKOUT

2026-10-30O $6.51H $6.67L $6.28C $6.67VOL 1.50M

RES: $4.32SUP: $1.76SMA50: $4.21SMA200: $4.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MYGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MYGN Butterfly Map → + Track MYGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MYGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MYGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MYGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MYGN)

Health Care Rank #667 of 1016 ⚔️ ACHV vs MYGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MYGN vs. ACHV, NNNN, TKNO, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Myriad Genetics Inc. (MYGN) ranks #667 by composite RQD confidence (39/100, grade D-) and #415 by equity capitalization ($638.0M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with MYGN at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MYGN ACTIVE Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	Benchmark Subject
ACHV Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-mygn →
NNNN Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-mygn →
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-mygn →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-mygn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899923

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Myriad Genetics Inc. (MYGN) reported GAAP revenue of $824.5M (-1.6% vs. FY2024 revenue of $837.6M , and +9.5% cumulative change since FY2023) , GAAP net income of -$366.0M, operating cash flow of $1.8M, and free cash flow of $1.8M (+120.7% YoY). On the balance sheet, MYGN closed FY2025 with $706.6M in total assets against $119.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$824.5M	-$366.0M	$1.8M	$1.8M	$706.6M	$119.9M
FY2024 (FY)	2024-12-31	$837.6M	-$127.0M	-$8.7M	-$8.7M	$1.03B	$39.6M
FY2023 (FY)	2023-12-31	$753.2M	-$263.0M	-$110.9M	-$110.9M	—	—

3. MYGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MYGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Myriad Genetics Inc. (NASDAQ: MYGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $6.67 (+0.60% 1D, market cap $638.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MYGN ranks #667 in composite RQD confidence.

How does MYGN compare to ACHV and NNNN in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), MYGN carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 69.9%, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $739.9M) and NNNN (Anbio Biotechnology (Class A)) posts a D grade (45/100 RQD, P/E 83.6x, ROIC 17.0%, cap $535.3M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MYGN?

Per MYGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899923), Myriad Genetics Inc. generated $824.5M in revenue (-1.6% YoY), -$366.0M in net income, and $1.8M in free cash flow against $706.6M in total assets and $119.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MYGN trading relative to its 50-day, 200-day, and 52-week technical levels?

MYGN last traded at $6.67 (+0.60% on volume of 1,470,889 shares), positioning the stock +58.43% above its 50-day simple moving average ($4.21) and +44.69% above its 200-day simple moving average ($4.61). Across its 52-week range of $2.74 to $8.38, MYGN sits at the 69.7% percentile with a 14-day RSI of 72.7 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.84 to $7.50).

MYGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Myriad Genetics Inc. (MYGN)?

In FY 2025 (10-K), MYGN converted $824.5M of revenue into a 69.9% gross margin, 0% operating margin, and $1.8M in free cash flow (0.2% FCF margin).

Direct Sub-Reports: MYGN RQD Cockpit MYGN 12M Forecast MYGN Earnings & Move MYGN Dividends & DRIP MYGN Insiders & 13F MYGN Whale Options MYGN Profit Sankey MYGN News & Why